Description: Panacea Biotec Limited, a biotechnology company, researches and develops, manufactures, markets, and sells pharmaceuticals, vaccines, and biosimilar in India. The company operates through Vaccines, Formulations, and Research and Development segments. Its product portfolio includes prescription products in various therapeutic areas, including pain management, diabetes and cardiovascular management, oncology, renal disease management, osteoporosis management, anti-tubercular, and gastro-intestinal care products, as well as vaccines. The company also exports its products to the Commonwealth of Independent States, Africa, the Middle East, and Asia. It has a collaboration agreement with Refana Inc. for the development, manufacturing, and distribution of the Covid-19 vaccine. Panacea Biotec Limited was founded in 1984 and is based in New Delhi, India.
Home Page: www.panaceabiotec.com
B-1 Extension/G-3
New Delhi,
110044
India
Phone:
91 11 4167 9000
Officers
| Name | Title |
|---|---|
| Mr. Soshil Kumar Jain | Founder & Chairman |
| Mr. Sandeep Jain | Joint MD & Exec. Director |
| Dr. Rajesh Jain Ph.D. | MD & Whole-Time Director |
| Mr. Devender Gupta | CFO & Head of Information Technology |
| Mr. Vinod Goel | Group CFO, Head of Legal, Company Sec. & Compliance Officer |
| Mr. Ankesh Jain | Director of Sales & Marketing and Whole-Time Director |
| Mr. Kulvinder Sarao | Sr. VP of Audit, Compliances & HR |
| Dr. Sukhjeet Singh | Chief Scientific Officer & RA (Pharma) |
| Mr. Gurinder Pal Singh | Sr. VP of Acute & Chronic Bus. |
| Dr. Rajeeva Kumar Mangalum | Chief Operating Officer |
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 17.4577 |
| Price-to-Book MRQ: | 3.8603 |
| Price-to-Sales TTM: | 2.1018 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |